Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Sep 2

PMID 39219906

Authors

Divya Rajagopal

Sulthan Al Rashid

Monisha Prasad

Mohammad Fareed

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have drawn a lot of interest lately for their therapeutic advantages over controlling blood sugar levels in the management of type 2 diabetes mellitus (T2DM). This review aims to provide an overview of the research that has been done on the neuroprotective, renoprotective, and cardioprotective effects of GLP-1 receptor agonists. Studies suggest that these medicines could provide protective benefits beyond glucose regulation, possibly reducing the risks of cardiovascular and renal issues; mechanisms underlying these advantages are still not fully understood. The review emphasizes how crucial it is to conduct more studies to determine the clinical significance and underlying mechanisms of these protective benefits. Improved knowledge of GLP-1 receptor agonists may result in T2DM treatment plans that improve neurological, cardiovascular, and renal function in addition to blood sugar control. Therefore, further research is necessary to fully understand the potential of GLP-1 receptor agonists in providing comprehensive protection against complications related to T2DM.

References

Gerstein H, Hart R, Colhoun H, Diaz R, Lakshmanan M, Botros F . The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020; 8(2):106-114. DOI: 10.1016/S2213-8587(19)30423-1. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Benn M, Emanuelsson F, Tybjaerg-Hansen A, Nordestgaard B . Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. Diabetologia. 2021; 64(7):1492-1503. DOI: 10.1007/s00125-021-05436-0. View

Husain M, Bain S, Holst A, Mark T, Rasmussen S, Lingvay I . Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020; 19(1):156. PMC: 7526237. DOI: 10.1186/s12933-020-01106-4. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

Gorriz J, Soler M, Navarro-Gonzalez J, Garcia-Carro C, Puchades M, DMarco L . GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. J Clin Med. 2020; 9(4). PMC: 7231090. DOI: 10.3390/jcm9040947. View

Sheahan K, Wahlberg E, Gilbert M . An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2019; 96(1133):156-161. PMC: 7042958. DOI: 10.1136/postgradmedj-2019-137186. View

Bethel M, Patel R, Merrill P, Lokhnygina Y, Buse J, Mentz R . Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2017; 6(2):105-113. DOI: 10.1016/S2213-8587(17)30412-6. View

Riddle M, Aronson R, Home P, Marre M, Niemoeller E, Miossec P . Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013; 36(9):2489-96. PMC: 3747925. DOI: 10.2337/dc12-2454. View

10.

Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E . Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017; 54(10):933-941. DOI: 10.1007/s00592-017-1031-9. View

11.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

12.

Greco E, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S . GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas). 2019; 55(6). PMC: 6630923. DOI: 10.3390/medicina55060233. View

13.

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

14.

Zakir M, Ahuja N, Surksha M, Sachdev R, Kalariya Y, Nasir M . Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways. Cureus. 2023; 15(9):e45835. PMC: 10594042. DOI: 10.7759/cureus.45835. View

15.

Anjana R, Deepa M, Pradeepa R, Mahanta J, Narain K, Das H . Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017; 5(8):585-596. DOI: 10.1016/S2213-8587(17)30174-2. View

16.

Maiorino M, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K . Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovasc Diabetol. 2021; 20(1):210. PMC: 8522255. DOI: 10.1186/s12933-021-01401-8. View

17.

Kang Y, Jung C . Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinol Metab (Seoul). 2016; 31(2):258-74. PMC: 4923410. DOI: 10.3803/EnM.2016.31.2.258. View

18.

Marso S, Poulter N, Nissen S, Nauck M, Zinman B, Daniels G . Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013; 166(5):823-30.e5. DOI: 10.1016/j.ahj.2013.07.012. View

19.

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

20.

Nauck M, Muller T . Incretin hormones and type 2 diabetes. Diabetologia. 2023; 66(10):1780-1795. PMC: 10474001. DOI: 10.1007/s00125-023-05956-x. View